Administration of cardiac mesenchymal cells modulates innate immunity in the acute phase of myocardial infarction in mice

Although cardiac mesenchymal cell (CMC) therapy mitigates post-infarct cardiac dysfunction, the underlying mechanisms remain unidentified. It is acknowledged that donor cells are neither appreciably retained nor meaningfully contribute to tissue regeneration—suggesting a paracrine-mediated mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yi, Nasr, Marjan, Guo, Yiru, Uchida, Shizuka, Weirick, Tyler, Li, Hong, Kim, Jae, Moore, Joseph B., Muthusamy, Senthilkumar, Bolli, Roberto, Wysoczynski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479609/
https://www.ncbi.nlm.nih.gov/pubmed/32901075
http://dx.doi.org/10.1038/s41598-020-71580-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479609/
https://www.ncbi.nlm.nih.gov/pubmed/32901075
http://dx.doi.org/10.1038/s41598-020-71580-z

Ejemplares similares